Regenxbio Sued for Alleged Misleading Claims About Gene Therapy RGX-111

Regenxbio Faces Class Action Lawsuit Amid Allegations of Misleading Statements

Regenxbio Inc. is currently embroiled in a class action lawsuit filed by DJS Law Group, which brings serious allegations against the company regarding misleading claims made about its gene therapy product, RGX-111. The lawsuit cites violations of the Securities Exchange Act of 1934, specifically focusing on Sections 10(b) and 20(a), and claims that Regenxbio failed to disclose critical adverse health data related to the safety and efficacy of RGX-111. During the class period defined from February 9, 2022, to January 27, 2026, the company reportedly made numerous public announcements touting the therapy's benefits while withholding information about a significant clinical incident, where a trial participant developed a tumor.

The FDA's decision to place a clinical hold on RGX-111, linked to this incident, serves as a pivotal moment justifying the lawsuit. The complaint asserts that the company’s public statements before the clinical hold were misleading and failed to provide a true picture of the risks associated with the therapy. The plaintiffs argue that Regenxbio’s actions resulted in investor losses and seek accountability through compensation for damages incurred following the FDA’s revelation about the clinical trial participant’s adverse event. This situation raises questions about transparency and governance within biotech firms, particularly in how they manage public communications and regulatory compliance concerning their experimental therapies.

In a statement, DJS Law Group emphasizes the importance of the claims as valuable assets that require diligent advocacy, focusing on maximizing recoveries for affected shareholders. The firm is calling on shareholders who purchased shares of Regenxbio during the specified period to join the class action. They note that participation in the case does not necessitate an appointment as lead plaintiff, aiming to facilitate broader involvement among investors who may have been affected by the unfolding events surrounding RGX-111.

The case highlights the ongoing challenges faced by companies in the biotech industry as they navigate complex regulatory environments and the need for clear communication with investors and the public. As Regenxbio grapples with the repercussions of this lawsuit, its response and any subsequent actions taken will be crucial in shaping stakeholder confidence moving forward.